Tags

Type your tag names separated by a space and hit enter

Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication.
Haematologica. 2003 Jun; 88(6):637-45.H

Abstract

BACKGROUND AND OBJECTIVES

The biological characteristics and the prognostic significance of the internal tandem duplication of the FLT3 (FLT3/ITD) were investigated in a series of de novo acute myeloid leukemia (AML) patients. One hundred and fifty-six adult patients with AML were included in the study. FLT3/ITD was detected in 41 (26%) patients (FLT3/ITD(+)).

DESIGN AND METHODS

The main differences observed between the groups with and without FLT3/ITD: a higher leukocyte count, a raised percentage of a normal karyotype and a more frequent M5 FAB diagnosis in the FLT3/ITD(+) patients. As regards the immunophenotype characteristics the FLT3/ITD(+) group very often expressed monocytic markers (CD36 and CD11b) and less commonly immature markers (CD34 and CD117). A promyelocytic-like immunophenotype pattern was also detected in a minority of these patients(4/36).

RESULTS

The FLT3/ITD(+) patients had a shorter overall survival, a shorter event-free survival and a higher probability of relapse. Minimal residual disease (MRD) was investigated in the FLT3/ITD(+) patients using flow cytometry. This technique had a sensitivity of 62% and a specificity of 83% in relapse prediction. Minimal residual disease analysis was hampered by the low number of patients with detectable aberrant immunophenotype.

INTERPRETATION AND CONCLUSIONS

A high frequency of changes in the phenotype and/or genotype pattern between diagnosis and relapse was detected (5/6). FLT3/ITD is a frequent molecular lesion in de novo adult AML and seems to be associated with a monocytic differentiation, a high leukocyte count and a poor prognosis. Immunophenotype and genotype patterns observed at relapse suggest that the FLT3/ITD(+) blasts may be genetically unstable and prone to clonal evolution. FLT3/ITD may not be a suitable target for minimal residual disease studies.

Authors+Show Affiliations

Laboratori d'Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12801839

Citation

Muñoz, Luz, et al. "Immunophenotypic Findings in Acute Myeloid Leukemia With FLT3 Internal Tandem Duplication." Haematologica, vol. 88, no. 6, 2003, pp. 637-45.
Muñoz L, Aventín A, Villamor N, et al. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. Haematologica. 2003;88(6):637-45.
Muñoz, L., Aventín, A., Villamor, N., Juncà, J., Acebedo, G., Domingo, A., Rozman, M., Torres, J. P., Tormo, M., & Nomdedéu, J. F. (2003). Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. Haematologica, 88(6), 637-45.
Muñoz L, et al. Immunophenotypic Findings in Acute Myeloid Leukemia With FLT3 Internal Tandem Duplication. Haematologica. 2003;88(6):637-45. PubMed PMID: 12801839.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. AU - Muñoz,Luz, AU - Aventín,Ana, AU - Villamor,Neus, AU - Juncà,Jordi, AU - Acebedo,Gemma, AU - Domingo,Alicia, AU - Rozman,María, AU - Torres,J Pio, AU - Tormo,Mar, AU - Nomdedéu,Josep F, PY - 2003/6/13/pubmed PY - 2004/1/30/medline PY - 2003/6/13/entrez SP - 637 EP - 45 JF - Haematologica JO - Haematologica VL - 88 IS - 6 N2 - BACKGROUND AND OBJECTIVES: The biological characteristics and the prognostic significance of the internal tandem duplication of the FLT3 (FLT3/ITD) were investigated in a series of de novo acute myeloid leukemia (AML) patients. One hundred and fifty-six adult patients with AML were included in the study. FLT3/ITD was detected in 41 (26%) patients (FLT3/ITD(+)). DESIGN AND METHODS: The main differences observed between the groups with and without FLT3/ITD: a higher leukocyte count, a raised percentage of a normal karyotype and a more frequent M5 FAB diagnosis in the FLT3/ITD(+) patients. As regards the immunophenotype characteristics the FLT3/ITD(+) group very often expressed monocytic markers (CD36 and CD11b) and less commonly immature markers (CD34 and CD117). A promyelocytic-like immunophenotype pattern was also detected in a minority of these patients(4/36). RESULTS: The FLT3/ITD(+) patients had a shorter overall survival, a shorter event-free survival and a higher probability of relapse. Minimal residual disease (MRD) was investigated in the FLT3/ITD(+) patients using flow cytometry. This technique had a sensitivity of 62% and a specificity of 83% in relapse prediction. Minimal residual disease analysis was hampered by the low number of patients with detectable aberrant immunophenotype. INTERPRETATION AND CONCLUSIONS: A high frequency of changes in the phenotype and/or genotype pattern between diagnosis and relapse was detected (5/6). FLT3/ITD is a frequent molecular lesion in de novo adult AML and seems to be associated with a monocytic differentiation, a high leukocyte count and a poor prognosis. Immunophenotype and genotype patterns observed at relapse suggest that the FLT3/ITD(+) blasts may be genetically unstable and prone to clonal evolution. FLT3/ITD may not be a suitable target for minimal residual disease studies. SN - 1592-8721 UR - https://www.unboundmedicine.com/medline/citation/12801839/Immunophenotypic_findings_in_acute_myeloid_leukemia_with_FLT3_internal_tandem_duplication_ L2 - https://www.diseaseinfosearch.org/result/4195 DB - PRIME DP - Unbound Medicine ER -